166 related articles for article (PubMed ID: 33073300)
21. Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
Torossian A; Broin N; Frentzel J; Daugrois C; Gandarillas S; Saati TA; Lamant L; Brousset P; Giuriato S; Espinos E
Haematologica; 2019 Jul; 104(7):1428-1439. PubMed ID: 30679328
[TBL] [Abstract][Full Text] [Related]
22. Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.
Guan J; Wolfstetter G; Siaw J; Chand D; Hugosson F; Palmer RH; Hallberg B
Oncotarget; 2017 Feb; 8(7):11566-11578. PubMed ID: 28030793
[TBL] [Abstract][Full Text] [Related]
23. Binding mechanism of inhibitors to p38α MAP kinase deciphered by using multiple replica Gaussian accelerated molecular dynamics and calculations of binding free energies.
Chen J; Wang W; Sun H; Pang L; Bao H
Comput Biol Med; 2021 Jul; 134():104485. PubMed ID: 33993013
[TBL] [Abstract][Full Text] [Related]
24. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J
Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400
[TBL] [Abstract][Full Text] [Related]
25. Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling.
Chen J; Wang J; Zhu W
Phys Chem Chem Phys; 2017 Nov; 19(44):30239-30248. PubMed ID: 29109998
[TBL] [Abstract][Full Text] [Related]
26. Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach.
Zhao Z; Bourne PE
J Chem Theory Comput; 2020 May; 16(5):3152-3161. PubMed ID: 32283024
[TBL] [Abstract][Full Text] [Related]
27. Anaplastic lymphoma kinase expression in small-cell lung cancer.
Kondoh C; Horio Y; Hayashi Y; Ebi H; Hida T; Hasegawa Y; Yatabe Y
Histopathology; 2019 Jul; 75(1):20-28. PubMed ID: 30790327
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation.
Ogata M; Hatachi Y; Ogata T; Satake H; Imai Y; Yasui H
Intern Med; 2019 Apr; 58(7):1029-1032. PubMed ID: 30449794
[TBL] [Abstract][Full Text] [Related]
29. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
30. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
[TBL] [Abstract][Full Text] [Related]
31. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
32. Role and targeting of anaplastic lymphoma kinase in cancer.
Della Corte CM; Viscardi G; Di Liello R; Fasano M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
Mol Cancer; 2018 Feb; 17(1):30. PubMed ID: 29455642
[TBL] [Abstract][Full Text] [Related]
33. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
34. Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations.
Li J; Huang Y; Wu M; Wu C; Li X; Bao J
Sci Rep; 2018 Jul; 8(1):10664. PubMed ID: 30006516
[TBL] [Abstract][Full Text] [Related]
35. F1174V mutation alters the ALK active conformation in response to Crizotinib in NSCLC: Insight from molecular simulations.
Dehghanian F; Kay M; Vallian S
J Mol Graph Model; 2017 Aug; 75():287-293. PubMed ID: 28622610
[TBL] [Abstract][Full Text] [Related]
36. Identification and biological evaluation of glycol diaryl ethers as novel anti-cancer agents through structure-based optimization of crizotinib.
Liu S; Liu X; Zhang X; Shi M; Wang H; Liu Y
Chem Biol Drug Des; 2018 Dec; 92(6):1972-1980. PubMed ID: 30025202
[TBL] [Abstract][Full Text] [Related]
37. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
39. Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer.
Ni Z; Wang X; Zhang T; Jin RZ
Comput Biol Chem; 2016 Dec; 65():54-60. PubMed ID: 27764703
[TBL] [Abstract][Full Text] [Related]
40. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]